Trastuzumab and HER2 Therapy: Cardiac Monitoring That Continues After the Infusion Stops
Trastuzumab-related cardiac dysfunction is often reversible in active therapy — and often forgotten in survivorship. A practical monitoring cadence for the years after HER2-directed treatment ends.
Trastuzumab-related cardiac dysfunction is the textbook example of a cardio-oncology story that is well managed during active therapy and quietly forgotten in survivorship. For most patients the dysfunction is reversible; for a real minority it persists or emerges later. This is a practical survivorship monitoring cadence for the years after HER2-directed treatment ends.
What actually happens on therapy
Trastuzumab causes reversible myocardial dysfunction in a meaningful minority of patients — the reported incidence range for asymptomatic LVEF decline is roughly 4–20%, with symptomatic heart failure in the low single digits. Prior anthracycline exposure, older age, hypertension, and baseline low-normal LVEF are the recognized risk multipliers. Dose is not the driver the way it is for anthracyclines.
The on-therapy monitoring pattern (context)
Baseline LVEF (echo or MUGA), then LVEF every 3 months during therapy, with hold-and-reassess thresholds at absolute LVEF < 50% or a decline of ≥ 10 percentage points from baseline. This is the reference schedule everyone in oncology knows. The gap is what happens after therapy ends.
Survivorship monitoring: the schedule most patients need
For patients with no on-therapy events and no anthracycline co-exposure: an echo at 6–12 months post-completion is reasonable, and if normal, spacing to every 3–5 years thereafter — with a low threshold to re-image for new symptoms.
For patients with any on-therapy LVEF drop (even if it recovered), documented symptomatic event, or anthracycline co-exposure: echo at 6 months post-completion, then annually for 2–3 years, then every 2–3 years indefinitely.
Global longitudinal strain, where available, is the most useful sensitivity signal in the preserved-LVEF group — a GLS worse than baseline by ≥ 15% warrants cardio-oncology consultation even with a normal LVEF number.
What to modify beyond the imaging cadence
Hypertension control (target < 130/80), LDL to ASCVD-risk-appropriate targets, glucose, and tobacco cessation. These are the primary-care levers that meaningfully change the trajectory. Continuing an ACE-I/ARB and beta-blocker that were started during on-therapy dysfunction is a common survivorship decision — do not stop them silently at a routine visit.
Escalation triggers
New dyspnea on exertion, resting tachycardia, orthopnea, unexplained weight gain, or a fall in exercise tolerance in a survivor with prior HER2-directed therapy warrants an echo within 2 weeks and cardio-oncology consultation. Do not wait for the surveillance interval.
The hand-off problem
The most common failure mode is not the wrong interval — it is that no one owns the interval. A survivor moves out of oncology follow-up, the primary-care physician does not know the on-therapy history, and the next echo happens only when symptoms are already present. A patient-owned transition-of-care plan carrying the exposure, on-therapy event history, and the next surveillance date closes that gap in a single line.
Frequently asked questions
- Do I need to continue an ACE-I or beta-blocker after HER2 therapy ends if LVEF recovered?
- Often yes, particularly if they were started for an on-therapy dysfunction event. Decisions to discontinue should be made in coordination with cardio-oncology, not silently at a routine visit.
- Is MUGA acceptable instead of echo in survivorship?
- It is acceptable for LVEF tracking but does not provide strain data. Echo with GLS is preferred where available, particularly for lower-risk long-term survivors who want to minimize cumulative radiation exposure.
- How does anthracycline co-exposure change things?
- It shifts the survivor into the higher-risk group. The interval becomes closer to the anthracycline cardiomyopathy cadence — annual for the first 2–3 years post-therapy, then every 2–3 years indefinitely.
- What about newer HER2 conjugates (T-DM1, T-DXd)?
- Cardiac signal is generally lower than trastuzumab alone but not zero. Follow the same on-therapy monitoring pattern, and in survivorship default to the anthracycline-co-exposure schedule if the patient received any anthracycline in the treatment course.